Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Celecoxib + OBP-801|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Celecoxib||Celebra||Celebra (celecoxib) is a COX-2 inhibitor FDA approved as an anti-inflammatory agent and for colorectal polyp reduction (FDA.gov) and also promotes apoptosis of tumor cells (PMID: 17909047).|
|OBP-801||YM753|YM-753||HDAC Inhibitor 38||OBP-801 (YM753) is a histone deacetylase inhibitor belonging to the cyclic peptide class, which may induce both cell cycle arrest and apoptosis (PMID: 18292931, PMID: 23900601, PMID: 32277670).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||urinary bladder cancer||not applicable||Celecoxib + OBP-801||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of Celebra (celecoxib) and OBP-801 resulted in a synergistic effect, demonstrating increased apoptotic activity and decreased tumor volume in xenograft models of bladder cancer (PMID: 27406983).||27406983|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|